A good family friend recently told me about this available over the counter drug in Canada. She has used it for a while now and has found tremendous amount of relief for RLS and other leg problems. I realize that most if not all the people on this blog do not live in Canada. Of course it might be available outside Canada as well. But I just wanted to let folks know about this because I am about to try it for my situation.
And while writing this I would like to share with everyone who responded to my post that for the past few days, couple of weeks in fact; I have been doing not too badly. My Neurologist is attempting to get me switched from Mirapex and Sinimet (spelling?) to Gabapentin which I have learned from past experiences I have to do very gradually. I am down from five or six Mirapex to three and sometimes I can get away with two. But on Sunday evening past I bravely attempted to go it on one Mirapex and had a real bad reaction for about four hours. It was then that I took another Mirapex and things began to level out again. I am still on the Sinimet which does not seem to be bothering me very much, but does bring me quick relief. So that's my update and now I am going to try Venixxa. Which in due course I will report on as well.
Lonely7
Servier Canada announces the launch of VENIXXA™, an over-the-counter oral treatment to relieve signs and symptoms of chronic venous disease and hemorrhoids
NEWS PROVIDED BY
Servier Canada Inc.
Nov 10, 2017, 06:00 ET
SHARE THIS ARTICLE
LAVAL, QC, Nov. 10, 2017 /CNW Telbec/ - Servier Canada announces that VENIXXATM (micronized purified flavonoid fraction, MPFF), is now available in pharmacies as an over-the-counter oral treatment for patients with mild-to-moderate chronic venous disease or hemorrhoidal disease. VENIXXATM has been extensively tested in various controlled trials and large registries and is currently available in more than 33 countries around the world.
Chronic venous disease of the legs is characterized by signs and symptoms ranging from a sensation of heavy and/or painful legs, night cramps,1spider and varicose veins, edema or ulcers. In the Vein Consult Program2—an international, observational survey completed by 6232 general practitioners, it was estimated that approximately 74% of adults suffer from mild-to-moderate chronic venous disease. "As physicians, we have very few options available for these patients apart from mechanical treatments such as compression stockings and endovenous procedures. Although these are very good alternatives, a treatment that addresses the inflammatory process and loss of venous tone related to venous disease is welcome" stated Dr. Douglas Hill, President of the Canadian Society of Phlebology.
Hemorrhoids are a common condition among adults in North America; it is estimated that at least 50% of the population +50 years old has suffered from hemorrhoids at one point in their life. The most common signs and symptoms related to this disease are pain, bleeding and discomfort.3
Patients often experience a decline in their quality of life as each of these diseases progresses.4
Servier Canada
The over-the-counter drug market is expanding in Canada, and Servier Canada is proud to enter this market. "The launch of VENIXXATM stems from Servier`s priority to provide effective and innovative treatment options, to Canadian patients. We will leverage our international expertise in vascular disease, to raise awareness of chronic venous disease, hemorrhoidal disease and their consequences, as well as to work with health care providers to ensure that patients are provided with appropriate care." stated Frederic Fasano, Chief Executive Officer of Servier Canada.
Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs.
Servier Canada was established in 1978 in Laval, Quebec and employs over 300 people across Canada. Servier Canada is currently marketing medicines in Cardiology, Hematology and Diabetes, and will soon market oncology products indicated as treatment options in hematological malignancies. For additional information please visit our website at servier.ca.